Haemophilus Influenzae Type b: Clinical Trials

19 trials for Haemophilus Influenzae Type b, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

17 completed, 1 active not recruiting, 1 terminated. 19 Phase 2, 1 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 219Completed 17, Active not recruiting 1, Terminated 1
Phase 31Active not recruiting 1

Follow Haemophilus Influenzae Type b: new trials by email Literature Review of Haemophilus Influenzae Type b trials Research Report on Haemophilus Influenzae Type b

Trials (filtered) newest first · largest first

All 19 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Phase II/III Study to Evaluate the Immunogenicity, Safety and Lot-to-lot Consistency of LBVD, a Fully Liquid Hexavalent Diphtheria-tetanus-whole Cell Pertussis-hepatitis B-poliovirus-Haemophilus Influenzae Type b Conjugate (DTwP-HepB-IPV-Hib) Vaccine, in Healthy Infants as Primary Series
LBVD, Pentavalent vaccine and Inactivated Polio vaccine - Diphtheria, Tetanus
Phase 2 / Phase 3Active not recruitingLG Chem11862025-05-302026-09-03
Safety and Immunogenicity of a Booster Dose of New Formulations of GlaxoSmithKline Biologicals' DTPa-HBV-IPV/Hib Vaccine (GSK217744)
Infanrix hexa, Prevenar 13, GSK217744 - Acellular Pertussis, Hepatitis B
Phase 2CompletedGlaxoSmithKline6572011-10-142020-07-17
Safety and Immunogenicity of New Formulations of GlaxoSmithKline Biologicals' DTPa-HBV-IPV/Hib Vaccine (GSK217744)
Infanrix hexa™, Prevenar 13®, GSK217744 - Tetanus, Poliomyelitis
Phase 2CompletedGlaxoSmithKline7212010-12-092018-08-20
Immunogenicity and Safety Study of GlaxoSmithKline Biologicals' GSK2202083A Vaccine Administered as a Booster Dose
GSK2202083A vaccine, Infanrix hexa™, Menjugate™ - Tetanus, Diphtheria
Phase 2CompletedGlaxoSmithKline3912010-08-182020-01-21
Study of GlaxoSmithKline Biologicals' GSK2202083A Vaccine in Healthy Infants
GSK2202083A vaccine, Prevenar 13®, Infanrix hexa™ - Tetanus, Hepatitis B
Phase 2CompletedGlaxoSmithKline4802010-05-172018-08-20
Study to Evaluate the Immunogenicity and Reactogenicity of a Booster Dose of GSK2036874A Vaccine in Healthy Toddlers
GSK2036874A vaccine, Zilbrix™/Hib vaccine, Poliorix™ - Haemophilus Influenzae Type b, Tetanus
Phase 2CompletedGlaxoSmithKline3122010-05-132019-10-01
Immunogenicity and Safety Study of GSK Biologicals' GSK2202083A Vaccine in Healthy Infants at 2, 3 and 4 Months of Age
GSK2202083A vaccine, 10-valent pneumococcal vaccine (GSK 1024850A), Infanrix hexa™ - Tetanus, Diphtheria
Phase 2CompletedGlaxoSmithKline4212009-08-132020-01-03
Study to Evaluate GSK Biologicals' GSK2197870A Vaccine Given as Primary Course in Infants
GSK2197870A, Prevenar™, Menitorix™ - Neisseria Meningitidis, Haemophilus Influenzae Type b
Phase 2CompletedGlaxoSmithKline2842009-06-242018-06-06
Feasibility Study of GlaxoSmithKline Biologicals' GSK2202083A Vaccine in Healthy Infants at 3, 5 and 11 Months of Age.
GSK2202083A vaccine, Infanrix hexa, Menjugate - Tetanus, Poliomyelitis
Phase 2TerminatedGlaxoSmithKline162009-04-012018-06-06
Immunogenicity and Reactogenicity of a Booster Dose of GSK Bio's DTPa-HBV-IPV/Hib Vaccine
Infanrix Hexa - Acellular Pertussis, Diphtheria
Phase 2CompletedGlaxoSmithKline4032008-02-012018-06-06
Immunogenicity and Safety of a DTPa-HBV-IPV/Hib Vaccine Given at 2, 3 and 4 Months of Age
Infanrix hexa Vaccine - Acellular Pertussis, Tetanus
Phase 2CompletedGlaxoSmithKline4502006-10-012016-11-04
Multicentre Booster & Immune Memory Study of a Booster Dose of GSK Biologicals' 10-valent Pneumococcal Conjugate Vaccine or a Single Dose of 23-valent Plain Polysaccharide Vaccine in Healthy Children Aged 11-18 Mths, Previously Vaccinated in Study 103488
Pneumococcal (vaccine) - Acellular Pertussis, Tetanus
Phase 2CompletedGlaxoSmithKline6892005-11-012016-09-23
Hib-MenCY-TT Vaccine Study Compared to Licensed Hib and Meningococcal Serogroup C Conjugate Vaccines
MenHibrix (Hib-MenCY-TT), Infanrix® Penta, Prevenar® - Neisseria Meningitidis, Haemophilus Influenzae Type b
Phase 2CompletedGlaxoSmithKline11042005-04-112018-07-19
Study of DTaP-IPV-Hep B-PRP~T Combined Vaccine Compared With PENTAXIM™ and ENGERIX B® PEDIATRICO in Argentinean Infants
DTaP-IPV-HB-PRP~T, DTaP-IPV//PRP~T combined vaccine & Recombinant hep B vaccine - Diphtheria, Tetanus
Phase 2CompletedSanofi Pasteur, a Sanofi Company6242004-10-012013-12-17
Comparison of GSKBiologicals' Hib-MenCY-TT Vaccine vs Licensed Hib Conjugate or Meningococcal Vaccine
GSK Biologicals' Haemophilus influenza type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine 792014 vaccine, ActHIB, Pediarix - Haemophilus Influenzae Type b, Neisseria Meningitidis
Phase 2CompletedGlaxoSmithKline7562004-08-012018-08-24
Immunogenicity, Safety & Reactogenicity of GSK Vaccine Tritanrix™-HepB/Hib2.5 Compared to GSK Vaccine Tritanrix™-HepB/Hiberix™
Tritanrix™-HepB low thio /, Hib 2.5, Tritanrix™-HepB - Haemophilus Influenzae Type b
Phase 2CompletedGlaxoSmithKline1922003-08-012016-09-09
A Study to Assess Antibody Persistence, Boostability & Safety in Previously Primed Subjects.
DTPw-HBV/Hib-MenAC conjugate vaccine - Haemophilus Influenzae Type b, Tetanus
Phase 2CompletedGlaxoSmithKline4502003-07-012016-09-09
Dose Ranging Study of Combined Haemophilus Influenzae Type B-Meningococcal Serogroups CY (Hib-MenCY-TT) Vaccine
Hib-MenCY-TT vaccine (MenHibrix), Meningitec®, ActHIB® - Haemophilus Influenzae Type b, Neisseria Meningitidis
Phase 2CompletedGlaxoSmithKline4092003-03-012018-08-27
3 Formulations of Hib-MenCY-TT Vaccine & 1 Formulation of Hib-MenC-TT Vaccine Compared to Licensed Meningococcal Serogroup C Conjugate Vaccine, Each Administered at 2,3,4 Mths of Age
Hib-MenCY-TT vaccine, Hib-MenC-TT vaccine, Menjugate ® - Haemophilus Influenzae Type b, Neisseria Meningitidis
Phase 2CompletedGlaxoSmithKline3882003-03-012018-08-27

Narrower conditions

Haemophilus Infections (19)  ·  Diphtheria (14)  ·  Hepatitis B (14)  ·  Tetanus (14)  ·  Poliomyelitis (11)  ·  Whooping Cough (3)  ·  Meningococcal Infections (1)

Broader conditions

Bacterial Infections (19)  ·  Bacterial Infections and Mycoses (19)  ·  Gram-Negative Bacterial Infections (19)  ·  Infections (19)  ·  Pasteurellaceae Infections (19)  ·  Actinomycetales Infections (14)  ·  Blood-Borne Infections (14)  ·  Clostridium Infections (14)  ·  Communicable Diseases (14)  ·  Corynebacterium Infections (14)  ·  DNA Virus Infections (14)  ·  Digestive System Diseases (14)  ·  Gram-Positive Bacterial Infections (14)  ·  Hepadnaviridae Infections (14)  ·  Hepatitis (14)

Interventions

diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine (9)  ·  Heptavalent Pneumococcal Conjugate Vaccine (4)  ·  13-valent pneumococcal vaccine (3)  ·  Haemophilus influenza type b polysaccharide vaccine-tetanus toxin conjugate (3)  ·  Hib-MenCY-TT vaccine (3)  ·  DTPa-HBV-IPV combined vaccine (2)  ·  10-valent pneumococcal vaccine (1)  ·  Chickenpox Vaccine (1)  ·  DTP-IPV-Hib vaccine (1)  ·  DTaP-IPV-HB-PRP-T vaccine (1)  ·  Haemophilus influenzae-type b polysaccharide-Neisseria meningitidis outer membrane protein conjugate vaccine (1)  ·  Hiberix (1)  ·  Meningococcal Vaccines (1)  ·  PEDIARIX (1)  ·  PHiD-CV vaccine (1)

Sponsors

GlaxoSmithKline (17)  ·  LG Chem (1)  ·  Sanofi Pasteur, a Sanofi Company (1)

Countries

Finland (4)  ·  Philippines (4)  ·  Germany (3)  ·  Australia (2)  ·  Dominican Republic (2)  ·  Poland (2)  ·  Argentina (1)  ·  Belgium (1)  ·  Canada (1)  ·  France (1)  ·  Slovakia (1)  ·  United Kingdom (1)  ·  United States (1)

Results publications

PMID 28340322, PMID 20657177, PMID 21372751

NIH funding

2009 (1), 2016 (1)